Roivant Sciences (NASDAQ:ROIV) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Roivant Sciences (NASDAQ:ROIV) announced its quarterly earnings results on Monday. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.04, Zacks reports. Roivant Sciences had a negative return on equity of 14.65% and a net margin of 3,827.42%.

Roivant Sciences Stock Performance

Shares of Roivant Sciences stock opened at $10.89 on Monday. The company has a market capitalization of $7.93 billion, a P/E ratio of 1.93 and a beta of 1.25. Roivant Sciences has a 1 year low of $9.76 and a 1 year high of $13.06. The company’s fifty day moving average is $11.51 and its two-hundred day moving average is $11.60.

Insider Activity

In related news, COO Eric Venker sold 100,000 shares of the stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $11.32, for a total transaction of $1,132,000.00. Following the completion of the sale, the chief operating officer now directly owns 606,525 shares of the company’s stock, valued at $6,865,863. This trade represents a 14.15 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Sciences Ltd. Roivant acquired 16,845,010 shares of the stock in a transaction that occurred on Monday, January 13th. The stock was purchased at an average price of $20.00 per share, for a total transaction of $336,900,200.00. Following the completion of the transaction, the director now owns 96,650,341 shares in the company, valued at $1,933,006,820. The trade was a 21.11 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders sold 1,942,629 shares of company stock valued at $23,034,486. Insiders own 7.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on ROIV. HC Wainwright restated a “buy” rating and set a $18.00 price objective on shares of Roivant Sciences in a research report on Wednesday, November 13th. Cantor Fitzgerald raised shares of Roivant Sciences to a “strong-buy” rating in a research report on Thursday, January 30th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $17.93.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.